Sofosbuvir - use for the treatment of chronic hepatitis C Hepcinat ? (Sofosbuvir) - a new drug developed by an Indian company Pharma Natco, Ltd. Geptsinat (sofosbuvir) Generic high quality is produced with the help of high technology equipment, according to all the necessary standards and requirements. Treatment with sofosbuvir is applied in a complex therapy withoutinterferonovoy in almost all leading clinics around the world, because this drug, the last table of laboratory and clinical... Read More
Sofosbuvir - use for the treatment of chronic hepatitis C Hepcinat ? (Sofosbuvir) - a new drug developed by an Indian company Pharma Natco, Ltd. Geptsinat (sofosbuvir) Generic high quality is produced with the help of high technology equipment, according to all the necessary standards and requirements. Treatment with sofosbuvir is applied in a complex therapy withoutinterferonovoy in almost all leading clinics around the world, because this drug, the last table of laboratory and clinical studies, has shown good results. The efficacy of the new drug in the first genotype of the virus is 94% of the doctors who achieved the best results when used with sofosbuvir + daklatasvir. These drugs are by far the most effective for the treatment of HCV. Almost a hundred percent in clinical trials was achieved even in patients with liver disease and in patients with a third genotype. But the problem is in their purchase, because they are not in the free market, to buy sofosbuvir quite difficult in Russia, but it is possible, You can Hepcinat (sofosbuvir India) to buy in our online store. On our site you can order not only sofosbuvir, which is the lowest price that can be found on the internet, but also sofosbuvir, reviews that go beyond all the expectations of the patients. sofosbuvir - instructions for use: The drug is a viral NS5B polymerase inhibitor and inhibits the HCV replication of sofosbuvir used for the treatment of chronic hepatitis C as a major component of antiviral therapy for adult patients in combination with other drugs. Clinical data confirm the high efficacy of the drug in a genotype of 1, 2, 3 and 4 on the efficacy of the drug in patients co-infected with HIV and hepatitis. Indications: Sofosbuvir has been approved for use in combination with other antiviral agents for the treatment of the first, second, third, and fourth hepatitis C genotype in adult patients. How to apply The medicine is taken once a day at a dose of 400 mg (1 tablet). Better not chew the tablet because it has a bitter taste. The medicine is best taken with food, consuming plenty of water. Take medication every day at the same time. Side Effects: Overall, the drug was well tolerated and did not have any pronounced side effects. The most common of them - it's fatigue, headache and nausea. The severity of side effects is increased in combination therapy with interferon and other antiviral medicines. Contraindications The medicine should not be taken: - Children and adolescents under the age of 18; - During pregnancy; - lactation; - In case of hypersensitivity to the active substance. The specified patient group can not be treated with sofosbuvir since clinical trials have been conducted for these groups. Women of reproductive age should be taken with caution, because now sofosbuvir impact on reproductive function is not clearly determined. Elderly patients and patients with renal and hepatic impairment should be treated only under strict medical supervision. No dose adjustment is necessary for mild renal insufficiency and hepatic impairment. Interaction with other medicines The medicine is only used in combination with other antiviral agents when the efficacy is greater than the possible complications. The medicine should not be combined with boceprevir or telaprevir. The therapeutic dose of 400 mg per day of the drug has no effect on the QT interval and does not cause any disruption of the cardiovascular system. Special instructions: - The treatment should only be performed under the strict supervision of the physician; - It is recommended to use the medicine in combination with other antiviral medicines; - monotherapy with sofosbuvir is not recommended; - the recommended dose for adults - 400 mg a day (1 tablet) during the meal; - Do not reduce the daily dose of medicine; - The drug has an unpleasant bitter taste, so it's better not to chew the drug and not share it; - If you have vomiting within two hours after taking the medicine - take one extra tablet; - if the vomiting occurred after two hours; - no extra tablet is needed; - When the medicine is not held in any way, immediately drink a missed tablet. The next time you can take a pill at the usual time; - During treatment, they refrain from activities that require speed and attention. Product: Oval tablets dose 400 mg. At 28 tablets per pack. Storage conditions: Keep the medicine in a dry place, sheltered from the sun and out of reach of children. Date of manufacture and date of retention on the packaging. Do not take the medicine after the expiry date shown on the pack. Keep this medicine at a temperature of 15 to 30 Hepattis C. What is Natdac? Natdac is an antiviral medicine that is used in combination with other medicines to treat hepatitis C in adults. The drug contains the active substance Daclatasvir that blocks the activity of a hepatitis C virus protein called "NS5A", which is essential for virus multiplication. By blocking this protein, the drug stops hepatitis C virus multiplication. There are several genotypes of hepatitis C virus and it has been shown that Daklinza is effective against genotypes 1 to 4. How is Natdac used? Daclatasvir can only be obtained with a prescription and treatment should be initiated and monitored by a physician experienced in the treatment of patients with chronic hepatitis C. It is available as 30 mg and 60 mg tablets. The usual dose is 60 mg once a day. Daclatasvir should be used in combination with other chronic hepatitis C medications such as sofosbuvir, peginterferon alfa and ribavirin. The combination of medication to be used and the duration of treatment will depend on the hepatitis C virus genotype the patient is infected with and the type of liver disease he or she has, for example, if he has cirrhosis (liver sclerosis) or if the patient's liver is no longer functioning suitable. For more information, see the prospectus. How does Natdac work? The active substance in Natdac, daclatasvir, blocks the activity of a hepatitis C virus called "NS5A", which is essential for virus multiplication. By blocking this protein, The drug stops the hepatitis C virus multiplication. There are several genotypes of hepatitis C virus and Daklinza has been shown to be effective against genotypes 1 to 4. What benefit has Daclatasvir shown during the studies? In a major study involving 211 adults, Daclatasvir used in combination with sofosbuvir (with or without ribavirin) has been shown to be effective in eliminating hepatitis C virus from the blood. Patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks. Most patients had not been previously treated for hepatitis C, Although some were infected with standard 1-drug resistant genotype (consisting of telaprevir or boceprevir - the so-called NS3 / 4A inhibitors - in combination with peginterferon alfa and ribavirin). Approximately 99% of patients with genotype 1 (125 out of 126), 96% of patients with genotype 2 (25 out of 26) and 89% of patients with genotype 3 (16 out of 18) Of the virus in the blood at 12 weeks after the end of the planned treatment. Additional studies involving patients with genotype 4 indicate that Daclatasvir is as effective against genotype 4 as against genotype 1. What are the associated risks? The most common side effects reported with Daclatasvir in combination with sofosbuvir, with or without ribavirin, Are exhaustion (fatigue), nausea and headache. For the full list of side effects reported with Daclatasvir, see the Package Leaflet. Daclatasvir is contraindicated with certain medicines that may reduce its effects. For more information on medicines that should not be taken with Daclatasvir, see the Package Leaflet.